14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
SLN vs LCTX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Lineage Cell Therapeutics, Inc. (LCTX) is the stronger overall head-to-head candidate over Silence Therapeutics Plc American Depository Share (SLN) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). SLN carries a Unified Composite Score of 45.6/100 (HOLD) at $19.81 (N/M Forward P/E, -11905.9% operating margin), whereas LCTX carries 54.9/100 (HOLD) at $0.77 (30.7x Forward P/E, -280.3% operating margin).
Growth vs. Quality Trade-Off: LCTX earns the overall head-to-head edge with a stronger Unified Composite Score (54.9/100 HOLD vs. SLN 45.6/100 HOLD) and 1.39β · 79% Vol risk profile, whereas SLN leads top-line expansion (+197.2% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: SLN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 77.5); meanwhile LCTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SLN vs LCTX. Trailing 12-month operating profitability (SLN -11905.9% vs LCTX -280.3%) and valuation multiples (SLN N/M vs LCTX 30.7x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $207.4M market capitalization and -280.3% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ SLN vs LCTX Key Questions & Quantitative Answers
As of Nov 20, 2026, Lineage Cell Therapeutics, Inc. (LCTX) is the stronger overall head-to-head candidate over Silence Therapeutics Plc American Depository Share (SLN) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). SLN carries a Unified Composite Score of 45.6/100 (HOLD) at $19.81 (N/M Forward P/E, -11905.9% operating margin), whereas LCTX carries 54.9/100 (HOLD) at $0.77 (30.7x Forward P/E, -280.3% operating margin). Growth vs. Quality Trade-Off: LCTX earns the overall head-to-head edge with a stronger Unified Composite Score (54.9/100 HOLD vs. SLN 45.6/100 HOLD) and 1.39β · 79% Vol risk profile, whereas SLN leads top-line expansion (+197.2% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: SLN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 77.5); meanwhile LCTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SLN leads the Growth & Scale pillar: SLN posts +197.2% YoY revenue growth and +0.0% YoY earnings growth on $456,000 TTM revenue (95.0% gross margin, -11905.9% operating margin), compared with LCTX at -61.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (-95.0% gross margin, -280.3% operating margin). On trailing 12-month operating scale, SLN generates $456,000 in USD-normalized revenue versus $11M for LCTX. In operating R&D and SG&A reinvestment, SLN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LCTX.
LCTX screens cheaper on headline valuation multiples. SLN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin), whereas LCTX trades at 30.7x Forward P/E, 30.7x Trailing P/E, 10.64x PEG, and 15.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SLN (-35.6% ROE) versus LCTX (4.3% ROE) capital efficiency.
In options market volatility and institutional positioning, SLN carries 55.4% implied volatility (50th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.77β · 4% Vol realized risk). By comparison, LCTX carries 0.0% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.39β · 79% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.